Moleculin Stock Financials

MBRX
 Stock
  

USD 1.45  0.05  3.33%   

Moleculin Biotech Average Assets are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Average Assets of 91.53 Million in 2021. Average Equity is likely to rise to about 89.9 M in 2022, whereas Net Income Per Employee is likely to drop (1 M) in 2022.
  
Refresh
With this module, you can analyze Moleculin financials for your investing period. You should be able to track the changes in Moleculin Biotech individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Total Debt

64,657.89

Share
Understanding current and past Moleculin Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Moleculin Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Moleculin Biotech's assets may result in an increase in income on the income statement.
The fundamental analysis of Moleculin Biotech is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Moleculin Biotech includes many different criteria found on its balance sheet. For example, investors should never minimize Moleculin Biotech's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Moleculin Biotech's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Moleculin Biotech.

Moleculin Biotech Cash

Chance Of Financial Distress
Over 51
Moleculin Biotech CS has more than 51 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Moleculin Biotech stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Moleculin Biotech's official financial statements usually reflect Moleculin Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Moleculin Biotech. For example, before you start analyzing numbers published by Moleculin accountants, it's critical to develop an understanding of what Moleculin Biotech's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Moleculin Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moleculin Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Moleculin Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moleculin Biotech CS. Please utilize our Beneish M Score to check the likelihood of Moleculin Biotech's management to manipulate its earnings.

Moleculin Biotech Company Summary

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001659617
CUSIP60855D200
RegionNorth America
LocationTexas; U.S.A
Business Address5300 Memorial Drive
New SymbolMBRX1
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.moleculin.com
Phone713 300 5160
CurrencyUSD - US Dollar
You should never invest in Moleculin Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Moleculin Stock, because this is throwing your money away. Analyzing the key information contained in Moleculin Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Moleculin Biotech Key Financial Ratios

Generally speaking, Moleculin Biotech's financial ratios allow both analysts and investors to convert raw data from Moleculin Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Moleculin Biotech over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Moleculin Biotech reports annually and quarterly.

Moleculin Biotech Key Balance Sheet Accounts

201720182019202020212022 (projected)
Accounts Payable810 K1.25 M2.15 M1.13 M1.36 M1.2 M
Total Assets19.48 M19.59 M25.23 M29.03 M84.09 M90.73 M
Current Assets8.3 M7.97 M13.48 M17.2 M72.5 M78.22 M
Assets Non Current11.18 M11.61 M11.75 M11.83 M11.59 M11.84 M
Cash and Equivalents7.71 M7.13 M10.73 M15.17 M70.9 M76.5 M
Total Debt450 K296 K276 K159 K63 K64.66 K
Shareholders Equity17.12 M14.27 M15.57 M17.76 M78.99 M85.23 M
Total Liabilities2.37 M5.31 M9.66 M11.27 M5.1 M5.52 M
Current Liabilities2.21 M3.88 M3.57 M2.92 M3.62 M3.35 M

Moleculin Biotech Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Moleculin Biotech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Earning Before Interest and Taxes EBIT(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Earning Before Interest and Taxes USD(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Net Income(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Net Income Common Stock(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Net Income Common Stock USD(9.8 M)(11.88 M)(13.21 M)(17.36 M)(15.89 M)(16.31 M)
Operating Expenses8.65 M15.03 M17.52 M19.74 M22.97 M18.6 M
Operating Income(8.65 M)(15.03 M)(17.52 M)(19.74 M)(22.97 M)(23.57 M)
Research and Development Expense4.54 M9.73 M11.01 M12.76 M14.42 M11.56 M
Selling General and Administrative Expense4.09 M5.23 M6.31 M6.79 M8.39 M6.9 M
Weighted Average Shares3.09 M4.32 M6.79 M9.85 M26.88 M29 M
Weighted Average Shares Diluted3.09 M4.32 M6.79 M9.85 M26.88 M29 M

Moleculin Biotech Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Moleculin Biotech. It measures of how well Moleculin is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Moleculin Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Moleculin had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Moleculin Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(28 K)(417 K)(51 K)(374 K)(19 K)(20.5 K)
Depreciation Amortization and Accretion18 K68 K199 K200 K164 K135.33 K
Net Cash Flow or Change in Cash and Cash Equivalents2.71 M(580 K)3.6 M4.44 M55.73 M60.13 M
Issuance Purchase of Equity Shares10.06 M12.04 M20.85 M22.57 M74.75 M80.65 M
Net Cash Flow from Financing10.06 M12.04 M20.85 M22.55 M74.72 M80.62 M
Net Cash Flow from Investing(28 K)(417 K)(51 K)(374 K)(19 K)(20.5 K)
Net Cash Flow from Operations(7.32 M)(12.2 M)(17.2 M)(17.77 M)(18.95 M)(19.45 M)
Share Based Compensation707 K1.14 M1.54 M1.68 M2.37 M2 M

Moleculin Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moleculin Biotech competition to find correlations between indicators driving Moleculin Biotech's intrinsic value. More Info.
Moleculin Biotech CS is considered to be number one stock in shares owned by institutions category among related companies. It is considered to be number one stock in shares outstanding category among related companies creating about  1,948,194  of Shares Outstanding per Shares Owned by Institutions. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Moleculin Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Moleculin Biotech's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.

Moleculin Biotech Systematic Risk

Moleculin Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Moleculin Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Moleculin Biotech correlated with the market. If Beta is less than 0 Moleculin Biotech generally moves in the opposite direction as compared to the market. If Moleculin Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Moleculin Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Moleculin Biotech is generally in the same direction as the market. If Beta > 1 Moleculin Biotech moves generally in the same direction as, but more than the movement of the benchmark.
.

About Moleculin Biotech Financials

What exactly are Moleculin Biotech Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Moleculin Biotech's income statement, its balance sheet, and the statement of cash flows. Potential Moleculin Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Moleculin Biotech investors may use each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Moleculin Biotech is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Moleculin grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Moleculin Biotech Thematic Clasifications

Moleculin Biotech CS is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical Products Idea
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas

Moleculin Biotech June 30, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Moleculin Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Moleculin Biotech CS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Moleculin Biotech CS based on widely used predictive technical indicators. In general, we focus on analyzing Moleculin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Moleculin Biotech's daily price indicators and compare them against related drivers.
Information Ratio(0.002379)
Maximum Drawdown17.61
Value At Risk(7.58)
Potential Upside5.04
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.